The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Study participants were randomly assigned to receive brentuximab vedotin plus lenalidomide and ... while 4.5% discontinued treatment. Adcetris is also indicated as monotherapy or in combination ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Patients with metastatic cancer had better quality of life, clinical outcomes, and sense of well-being when they regularly ...

Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...

This release contains forward-looking information about Pfizer Oncology and ADCETRIS (brentuximab vedotin), including its potential benefits, an approval in the U.S. for ADCETRIS in combination ...